Nat Prod Sci.  2018 Sep;24(3):194-198. 10.20307/nps.2018.24.3.194.

Chemicals from Cimicifuga dahurica and Their Inhibitory Effects on Pro-inflammatory Cytokine Production by LPS-stimulated Bone Marrow-derived Dendritic Cells

• Thao NP
• Lee YS
• Luyen BT
• Oanh HV
• Ali I
• Arooj M
• Koh YS
• Yang SY
• Kim YH

• KMID: 2422012
• DOI: http://doi.org/10.20307/nps.2018.24.3.194

Abstract

Inflammation is a biological response caused by overactivation of the immune system and is controlled by immune cells via a variety of cytokines. The overproduction of pro-inflammatory cytokines enhances abnormal host immunity, resulting in diseases such as rheumatoid arthritis, cardiovascular disease, Alzheimer's disease, and cancer. Inhibiting the production of pro-inflammatory cytokines such as interleukin (IL)-12p40, IL-6, and tumor necrosis factor (TNF)-α might be one way to treat these conditions. Here, we investigated the anti-inflammatory activity of compounds isolated from Cimicifuga dahurica (Turcz.) Maxim., which is traditionally used as an antipyretic and analgesic in Korea. In primary cell culture assays, 12 compounds were found to inhibit the production of pro-inflammatory cytokines (IL-12p40, IL-6, and TNF-α) in vitro in bone marrow-derived dendritic cells stimulated with LPS.

Keyword

Cimicifuga dahurica; Ranunculaceae; Anti-inflammatory; IL-12 p40; IL-6,TNF-α

MeSH Terms

Alzheimer Disease
Arthritis, Rheumatoid
Cardiovascular Diseases
Cimicifuga*
Cytokines
Dendritic Cells*
Immune System
In Vitro Techniques
Inflammation
Interleukin-6
Interleukins
Korea
Primary Cell Culture
Ranunculaceae
Tumor Necrosis Factor-alpha
Cytokines
Interleukin-6
Interleukins
Tumor Necrosis Factor-alpha

Figure

• 

  Fig. 1 Structures of compounds 1 – 12 isolated from C. dahurica

Reference

1. Schwab JM, Serhan CN. Curr Opin Pharmacol. 2006; 6:414–420.

2. Efron PA, Tsujimoto H, Bahjat FR, Ungaro R, Debernardis J, Tannahill C, Baker HV, Edwards CK, Moldawer LL. J Endotoxin Res. 2005; 11:145–160.

3. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V, Palucka AK, Banchereau J. Immunol Rev. 2007; 219:118–142.

4. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC. Proc Natl Acad Sci U S A. 1991; 88:4143–4147.

5. Kishimoto T. Int Immunol. 2010; 22:347–352.

6. Gahring LC, Carlson NG, Kulmar RA, Rogers SW. Neuroimmunomodulation. 1996; 3:289–303.

7. Beutler B, Cerami A. Nature. 1986; 320:584–588.

8. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. 1. china: China Medical Science and Technology Press;2010. p. 68–69.

9. Qin R, Zhao Y, Zhao Y, Zhou W, Lv C, Lu J. Fitoterapia. 2016; 115:52–56.

10. Zhang LL, Si JY, Zhang LJ, Xiao-Wei H, Lin L, Li RY, Chen D, Cao L. Chin J Integr Med. 2016; 1–9.

11. Tian Z, Si J, Chang Q, Zhou L, Chen S, Xiao P, Wu E. BMC Cancer. 2007; 7:237.

12. Lv C, Yang F, Qin R, Qi Z, Zhou W, Lu J. Bioorg Med Chem Lett. 2017; 27:3305–3309.

13. Thao NP, Kim JH, Thuy Luyen BT, Dat NT, Kim YH. Int J Biol Macromol. 2017; 98:526–534.

14. Thao NP, Luyen BT, Lee JS, Kim JH, Kim YH. Bioorg Med Chem Lett. 2017; 27:1874–1879.

15. Thao NP, Luyen BTT, Lee JS, Kim JH, Dat NT, Kim YH. J Nat Prod. 2017; 80:1867–1875.